<DOC>
	<DOCNO>NCT00506506</DOCNO>
	<brief_summary>N-acetylcysteine use reduce risk injury kidney administration contrast dye . The mechanism effectiveness intervention substantiate literature . The investigator hypothesize serum creatinine low patient receive NAC compare receive placebo serum cystatin C change patient receive NAC compare receive placebo . Also urine creatinine increase administration NAC compare administration NAC .</brief_summary>
	<brief_title>Effect N-Acetylcysteine ( NAC ) Creatinine Chronic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>1 . Patients eGFR 3060 ml/min calculate use last available creatinine patient weight . 2 . Age &gt; 18 3 . No known allergy adverse effect NAC 4 . No know schedule radiocontrast procedure 5 . No medication know affect creatinine secretion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>N-acetylcysteine</keyword>
	<keyword>Chronic kidney disease</keyword>
	<keyword>eGFR</keyword>
	<keyword>Cystatin C</keyword>
	<keyword>proteinuria</keyword>
	<keyword>Stage 3 chronic kidney disease</keyword>
</DOC>